Founded and jointly incubated by ARCH Venture Partners and Foresite Labs, and co-founded by Dr. David Baker of the UW Medicine Institute for Protein Design, Xaira launches with more than $1 billion in committed capital in support of its mission. The executive team also includes co-founder Dr. Hetu Kamisetty, formerly of Meta and the Institute for Protein Design; Dr. Arvind Rajpal, formerly of Genentech; and Dr. Don Kirkpatrick, formerly of Interline and Genentech.Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. In starting Xaira, we have brought together incredible multidisciplinary talent and capabilities at the right time to reimagine our entire approach, from drug discovery to clinical development.Xaira is led by renowned scientist Dr. Marc Tessier-Lavigne, former Chief Scientific Officer of Genentech and former President of Rockefeller and Stanford Universities. Other executives include co-founder Dr. Hetu Kamisetty, formerly of Meta and the Institute for Protein Design; Dr. Arvind Rajpal, formerly of Genentech; and Dr. Don Kirkpatrick, formerly of Interline and Genentech.In my previous roles, I witnessed an earlier generation of technologies fundamentally change drug discovery, delivering new medicines that alleviate the burden of disease for many patients, said Dr. Marc Tessier-Lavigne, CEO. Chair, Advisory Board, the Institute for Protein Design; Co-Founder and Chief Investment Officer, Sahsen Ventures; former CIO Quadra/Quellos and Blackrock Alternative AdvisorsXaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease.